Adagene (ADAG) Common Equity (2019 - 2025)
Adagene's (ADAG) quarterly Common Equity came in at $35349.5 billion in Q4 2025, down 30.03% year-on-year from $50523.8 billion in Q4 2024, and up 93241469.26% on a QoQ basis from $37.9 million in Q2 2025.
Adagene (ADAG) Common Equity (2019 - 2025) Analysis & Trends
Adagene (ADAG) has 7 years of Common Equity data on file, last reported at $35349.5 billion in Q4 2025.
- On a quarterly basis, Common Equity fell 30.03% year-over-year to $35349.5 billion in Q4 2025; TTM through Dec 2025 was $35349.5 billion, a 30.03% decrease from a year earlier, with the FY2025 full-year figure at $35349.5 billion, down 30.03% from the prior year.
- Common Equity for Q4 2025 stood at $35349.5 billion, up from $37.9 million in the prior quarter.
- Over the last five years, Common Equity for ADAG reached as high as $112684.1 billion in Q2 2022 and fell as low as $37.9 million in Q2 2025.
- Historically, Common Equity has averaged $43500.1 billion across 5 years, with a median of $42936.7 billion in 2024.
- Across the five-year window, Common Equity surged 60510309.18% in 2022 and tumbled 100.0% in 2024, its largest moves.
- Year by year, Common Equity stood at $156.6 million in 2021, then soared by 53072864.39% to $83090.4 billion in 2022, then decreased by 15.08% to $70559.5 billion in 2023, then dropped by 28.4% to $50523.8 billion in 2024, then slumped by 30.03% to $35349.5 billion in 2025.
- Per Business Quant data, the three most recent Common Equity figures were $35349.5 billion in Q4 2025, $37.9 million in Q2 2025, and $50523.8 billion in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | Adagene | 198.85 Mn | 198.85 Mn | - | 35,349.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 35,349.55 Bn |
| Jun 30, 2025 | 37.91 Mn |
| Dec 31, 2024 | 50,523.84 Bn |
| Jun 30, 2024 | 56.59 Mn |
| Dec 31, 2023 | 70,559.50 Bn |
| Jun 30, 2023 | 82,793.53 Bn |
| Dec 31, 2022 | 83,090.35 Bn |
| Jun 30, 2022 | 112,684.12 Bn |
| Dec 31, 2021 | 156.56 Mn |
| Jun 30, 2021 | 186.22 Mn |
| Dec 31, 2020 | -89.39 Mn |
| Dec 31, 2019 | -57.01 Mn |